logo-loader

Verona Pharma's chief medical officer to quit at the end of the month

Published: 07:49 11 Apr 2018 BST

doctor looking at lung x-ray
The company is developing a drug for chronic obstructive pulmonary disease

Respiratory specialist Verona Pharma PLC (LON:VRP, NASDAQ:VRNA) said its chief medical officer, Kenneth Newman, is quitting the company at the end of the month to “pursue other opportunities”.

The search is already underway for his replacement.

WATCH: Can Verona Pharma hit the dizzy heights of 5p again?

Chief executive Jan-Anders Karlsson thanked Newman for his “outstanding service” over the past three years.

This included the acceleration into phase IIb clinical trials of Verona’s chronic obstructive pulmonary disease drug candidate.

In total, Newman oversaw seven clinical trials and played an instrumental role in establishing the drug developer’s US presence.

Oriole Resources outlines 2023 achievements and future exploration plans

Oriole Resources PLC (AIM:ORR) CEO Tim Livesey and chief financial officer Bob Smeeton join Proactive's Stephen Gunnion with details of the company's 2023 financial and operational performance. Livesey highlighted successful exploration programs in Cameroon, at the Bibemi and Mbe projects,...

2 hours, 35 minutes ago